(INFU) InfuSystems Holdings - Ratings and Ratios

InfuSystem Holdings, Inc. specializes in providing comprehensive infusion solutions, including ambulatory infusion pumps and associated disposable supply kits, primarily to oncology and infusion clinics across the United States and Canada. The company operates through two distinct segments: Patient Services and Device Solutions. Its product portfolio caters to the treatment of various cancers, including colorectal, breast, and lung cancers, as well as pain management and other chronic conditions. Beyond equipment provision, InfuSystem offers biomedical services such as recertification, maintenance, and repair, ensuring compliance with regulatory standards. Additionally, the company provides customer support through local representatives and operates service centers for equipment maintenance. Incorporated in 2005, InfuSystem is headquartered in Rochester Hills, Michigan.

InfuSystems services extend to selling, renting, and leasing new and pre-owned medical equipment, including pole-mounted and ambulatory infusion pumps. The company also distributes treatment-related consumables, enhancing its role as a one-stop solution for healthcare providers. Its customer base includes hospitals, home care providers, skilled nursing facilities, and pain centers, underscoring its broad impact on healthcare delivery. By focusing on both patient services and device solutions, InfuSystem supports the continuum of care in oncology and beyond.

3-Month Forecast: - Technical Outlook: INFUs price is below its SMA20 and SMA50, suggesting potential bearish momentum. The stock may face resistance at $8.01 (SMA20) and $8.09 (SMA50). Support is anticipated near $7.30 (SMA200). With an ATR of 0.35, moderate volatility is expected. - Fundamental Outlook: The high P/E ratio of 116 indicates a premium valuation, while a P/B ratio of 3.11 suggests the stock is pricey relative to book value. A P/S ratio of 1.30 reflects moderate revenue valuation. The low RoE of 2.67% may signal underperformance in profitability. Overall, the forecast leans neutral to slightly bearish, with potential price stabilization near key moving averages.